Overview

Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the best dose of the combination of two approved drugs, intravenous topotecan and oral erlotinib.
Phase:
Phase 1
Details
Lead Sponsor:
Accelerated Community Oncology Research Network
Collaborators:
Genentech, Inc.
GlaxoSmithKline
Treatments:
Erlotinib Hydrochloride
Topotecan